Non squamous non-small cell lung cancer
Conditions
Interventions
Bevacizumab combined with chemotherapy group (A chemotherapy regimen that includes all chemotherapy drugs):None
Bevacizumab combined with TKI group (TKI drugs (including but not limited to ositinib, erlotinib, gefitinib, extinib, ametinib, aletinib, dacetinib, fumetinib, afatinib)):None
Bevacizumab combined with immunotherapy group (Immunotherapy drugs (including but not limited to Xindilizumab, Karelizumab, Pabolizumab, Nafenumab, Treprizumab, Tirelizumab, Sepalizumab, Pa'anprizumab
Sponsors
Jiangsu Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1) Visit on January 1, 2023 to December 31, 2023; 2) Age = 18 years old; 3) Locally advanced, recurrent, or metastatic non-small cell lung cancer confirmed by histology or cytology as inoperable; Indications for the use of bevacizumab according to clinical diagnosis and treatment conventions; 4) ECOG score 0-1 points; 5) Accept a treatment regimen containing bevacizumab combined with chemotherapy/TKI/immunotherapy.
Exclusion criteria
Exclusion criteria: 1) Merge patients with other malignant tumors; 2) Individuals who are allergic to bevacizumab and its excipients; 3) Individuals with severe damage to the liver, kidneys, hematopoiesis, and cardiovascular system; 4) Pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression free survival;Objective relief rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of adverse reactions;Type and severity of adverse reactions; | — |
Countries
China
Contacts
Public ContactShaorong YU
Jiangsu Cancer Hospital
Outcome results
None listed